{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:51:02Z","timestamp":1769763062220,"version":"3.49.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Acute leukemia is an aggressive, highly heterogeneous hematological malignancy. A Disintegrin And Metalloproteinase Domain-6 (ADAM6), a member of ADAMs family, has emerged recently as a potential novel player in pediatric acute lymphoblastic leukemia (ALL), and its function remains largely elusive. Serine Protease-1 (PRSS1) is another emerging molecular mediator in cancer development. However, its role in acute leukemia has not been adequately studied. Interestingly, ADAM6 and PRSS1 were identified among the genes with the highest percentage of chromosomal changes in profiled B-cell precursor ALL patients. Both are emerging novel mediators of extracellular matrix (ECM) remodeling. Thus, this study was designed to investigate the roles of ADAM6 and PRSS1 in ALL and acute myeloid leukemia (AML) in adults.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Adult patients with de novo ALL (<jats:italic>n<\/jats:italic>\u2009=\u200936), de novo AML (<jats:italic>n<\/jats:italic>\u2009=\u200940), and healthy control subjects (<jats:italic>n<\/jats:italic>\u2009=\u200955) were enrolled in this study. Circulating serum levels of ADAM6 and PRSS1 were measured by ELISA technique.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Serum levels of ADAM6 were significantly higher in ALL and AML patients compared to healthy control subjects (208.7(178.3\u2013337.3), 186.4(155.3\u2013479.6), and 78.6(55.8\u2013101.8) pg\/ml, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.0001<\/jats:italic>), respectively. Whereas, serum levels of PRSS1 were found to be significantly lower in ALL and AML patients compared to healthy controls (175.1(153.7\u2013232.2), 177.9(145.3\u2013206.4), and 247.5(204.3\u2013375.3) ng\/ml, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.0001<\/jats:italic>), respectively. Both ADAM6 and PRSS1 exhibited a very good diagnostic potential by ROC analyses. ADAM6 levels significantly varied between CD22<jats:sup>+<\/jats:sup>\/CD22<jats:sup>\u2212<\/jats:sup> and CD45<jats:sup>+<\/jats:sup>\/CD45<jats:sup>\u2212<\/jats:sup>, while PRSS1 levels significantly varied between HLA-DR<jats:sup>+<\/jats:sup>\/HLA-DR<jats:sup>\u2212<\/jats:sup> ALL patients, suggesting their prognostic implications. Also, ADAM6 and PRSS1 were found to be significantly correlated with each other.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The results of the current study portray ADAM6 and PRSS1 as new potential diagnostic\/prognostic biomarkers and potential therapeutic targets in adult acute leukemia patients, and shed light on their role as novel interrelated mediators possibly implicated in tumor micro-environment remodeling.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n            <jats:p>This figure was created in BioRender. Kassem, D. (2025) <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/BioRender.com\/tf8iofn\" ext-link-type=\"uri\">https:\/\/BioRender.com\/tf8iofn<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14292-9","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T06:28:23Z","timestamp":1747463303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging roles of ADAM6 and PRSS1 as novel diagnostic\/prognostic biomarkers for acute lymphoblastic and myeloid leukemia in adults"],"prefix":"10.1186","volume":"25","author":[{"given":"Heba M.","family":"Anis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3999-6656","authenticated-orcid":false,"given":"Nahed M.","family":"Rakha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5102-3235","authenticated-orcid":false,"given":"Dina H.","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-6920","authenticated-orcid":false,"given":"Amany M.","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"1","key":"14292_CR1","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","volume":"5","author":"A Miranda-Filho","year":"2018","unstructured":"Miranda-Filho A, Pi\u00f1eros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5(1):e14\u201324.","journal-title":"Lancet Haematol"},{"key":"14292_CR2","unstructured":"WHO. Global Cancer Observatory - Globocan 2022. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/36-leukaemia-fact-sheet.pdf. 2022."},{"key":"14292_CR3","doi-asserted-by":"publisher","unstructured":"Harrison CJ, Johansson B. Acute lymphoblastic leukemia. In: Heim S, Mitelman F, editors. Cancer Cytogenetics. 2015. https:\/\/doi.org\/10.1002\/9781118795569.ch10.","DOI":"10.1002\/9781118795569.ch10"},{"key":"14292_CR4","doi-asserted-by":"publisher","unstructured":"Johansson B, Harrison CJ. Acute myeloid leukemia. In: Heim S, F Mitelman, editors. Cancer Cytogenetics. 2015. https:\/\/doi.org\/10.1002\/9781118795569.ch6.","DOI":"10.1002\/9781118795569.ch6"},{"issue":"24","key":"14292_CR5","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.3390\/cancers16244136","volume":"16","author":"C Wemyss","year":"2024","unstructured":"Wemyss C, Jones E, Stentz R, Carding SR. Acute Myeloid Leukaemia and acute lymphoblastic leukaemia classification and metabolic characteristics for informing and advancing treatment. Cancers. 2024;16(24):4136.","journal-title":"Cancers"},{"issue":"1","key":"14292_CR6","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2(1):16010.","journal-title":"Nat Rev Dis Primers"},{"key":"14292_CR7","unstructured":"ACS. American cancer society, cancer facts & figures 2025. Atlanta : American Cancer Society; 2025."},{"issue":"9","key":"14292_CR8","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/cancers13092256","volume":"13","author":"CK Tebbi","year":"2021","unstructured":"Tebbi CK. Etiology of acute leukemia: a review. Cancers. 2021;13(9):2256.","journal-title":"Cancers"},{"key":"14292_CR9","unstructured":"ACS. American cancer society. https:\/\/www.cancer.org\/cancer\/types\/acute-lymphocytic-leukemia\/about\/key-statistics.html#:~:text=Overall%2C%20about%204%20of%20every,is%20about%201%20in%201%2C000. 2025."},{"issue":"5","key":"14292_CR10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cncr.24862","volume":"116","author":"S Faderl","year":"2010","unstructured":"Faderl S, O\u2019Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116(5):1165\u201376.","journal-title":"Cancer"},{"issue":"10","key":"14292_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/jamaoncol.2018.1915","volume":"4","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia. JAMA Oncol. 2018;4(10):1413\u201320.","journal-title":"JAMA Oncol"},{"issue":"5","key":"14292_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.4103\/jcrt.jcrt_809_21","volume":"19","author":"RK Venugopalan","year":"2023","unstructured":"Venugopalan RK, Singh N, Anthony ML, Kunnumbrath A, Gupta AK, Nath UK, et al. Leukemia-associated aberrant immunophenotype: a flow cytometry-based experience of 110 cases from a tertiary care center in Northern India. J Cancer Res Ther. 2023;19(5):1335\u20139.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"14292_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1309\/AJCPO58YWIBUBESX","volume":"144","author":"CS Wilson","year":"2015","unstructured":"Wilson CS, Medeiros LJ. Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol. 2015;144(2):219\u201339.","journal-title":"Am J Clin Pathol"},{"key":"14292_CR14","doi-asserted-by":"publisher","first-page":"1105900","DOI":"10.3389\/fgene.2023.1105900","volume":"14","author":"B Ma","year":"2023","unstructured":"Ma B, Yu R. Pan-cancer analysis of ADAMs: a promising biomarker for prognosis and response to chemotherapy and immunotherapy. Front Genet. 2023;14:1105900.","journal-title":"Front Genet"},{"key":"14292_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bcp.2019.03.033","volume":"164","author":"S Zhong","year":"2019","unstructured":"Zhong S, Khalil RA. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease. Biochem Pharmacol. 2019;164:188\u2013204.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"14292_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.mam.2008.08.001","volume":"29","author":"DR Edwards","year":"2008","unstructured":"Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008;29(5):258\u201389.","journal-title":"Mol Aspects Med"},{"issue":"1\u20132","key":"14292_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cca.2009.01.007","volume":"403","author":"MJ Duffy","year":"2009","unstructured":"Duffy MJ, McKiernan E, O\u2019Donovan N, McGowan PM. The role of ADAMs in disease pathophysiology. Clin Chim Acta. 2009;403(1\u20132):31\u20136.","journal-title":"Clin Chim Acta"},{"issue":"8","key":"14292_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41388-022-02583-5","volume":"42","author":"J Arai","year":"2023","unstructured":"Arai J, Otoyama Y, Nozawa H, Kato N, Yoshida H. The immunological role of ADAMs in the field of gastroenterological chronic inflammatory diseases and cancers: a review. Oncogene. 2023;42(8):549\u201358.","journal-title":"Oncogene"},{"issue":"5","key":"14292_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1349-7006.2007.00434.x","volume":"98","author":"S Mochizuki","year":"2007","unstructured":"Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98(5):621\u20138.","journal-title":"Cancer Sci"},{"key":"14292_CR20","doi-asserted-by":"publisher","first-page":"706129","DOI":"10.3389\/fcell.2021.706129","volume":"9","author":"L Alsuwaidi","year":"2021","unstructured":"Alsuwaidi L, Hachim M, Senok A. Novel markers in pediatric acute lymphoid leukemia: the role of ADAM6 in B cell leukemia. Front Cell Dev Biol. 2021;9:706129.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"14292_CR21","first-page":"1","volume":"2","author":"JA Batista-Gomes","year":"2020","unstructured":"Batista-Gomes JA, Mello FAR, de Souza MPC, Wanderley AV, de Oliveira EHC, Khayat AS. ADAM3A deletion is associated with high-risk features in acute lymphoblastic leukemia. World Acad Sci J. 2020;2(5):1\u20137.","journal-title":"World Acad Sci J"},{"issue":"4","key":"14292_CR22","first-page":"950","volume":"23","author":"S Ma","year":"2015","unstructured":"Ma S, Xu J, Wang X, Wu QY, Cao J, Li ZY, et al. Effect of ADAM10 inhibitor GI254023X on proliferation and apoptosis of acute T-lymphoblastic leukemia jurkat cells in vitro and its possible mechanisms. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(4):950\u20135.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"key":"14292_CR23","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1186\/1471-2407-14-963","volume":"14","author":"G Tota","year":"2014","unstructured":"Tota G, Coccaro N, Zagaria A, et al. ADAMTS2 gene dysregulation in T\/myeloid mixed phenotype acute leukemia. BMC Cancer. 2014;14:963. https:\/\/doi.org\/10.1186\/1471-2407-14-963.","journal-title":"BMC Cancer."},{"key":"14292_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.canlet.2018.10.028","volume":"442","author":"JM Zhang","year":"2019","unstructured":"Zhang JM, Wang CC, Zhang GC, Jiang Q, Yang SM, Fu HX, et al. ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Lett. 2019;442:193\u2013201.","journal-title":"Cancer Lett"},{"issue":"11","key":"14292_CR25","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.leukres.2015.08.006","volume":"39","author":"XH Zhang","year":"2015","unstructured":"Zhang XH, Wang CC, Jiang Q, Yang SM, Jiang H, Lu J, et al. ADAM28 overexpression regulated via the PI3K\/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia. Leuk Res. 2015;39(11):1229\u201338.","journal-title":"Leuk Res"},{"issue":"13","key":"14292_CR26","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1111\/febs.16870","volume":"291","author":"D Rosenbaum","year":"2024","unstructured":"Rosenbaum D, Saftig P. New insights into the function and pathophysiology of the ectodomain sheddase A Disintegrin and metalloproteinase 10 (ADAM10). FEBS J. 2024;291(13):2733\u201366.","journal-title":"FEBS J"},{"issue":"10","key":"14292_CR27","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/leu.2011.130","volume":"25","author":"ML Sulis","year":"2011","unstructured":"Sulis ML, Saftig P, Ferrando AA. Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL. Leukemia. 2011;25(10):1564\u20139.","journal-title":"Leukemia"},{"key":"14292_CR28","doi-asserted-by":"publisher","first-page":"106665","DOI":"10.1016\/j.leukres.2021.106665","volume":"110","author":"RA Harris","year":"2021","unstructured":"Harris RA, Stevens JM, Pickering DL, Althof PA, Smith LM, Sanmann JN, et al. Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia. Leuk Res. 2021;110:106665.","journal-title":"Leuk Res"},{"issue":"6","key":"14292_CR29","doi-asserted-by":"publisher","first-page":"G466","DOI":"10.1152\/ajpgi.00419.2013","volume":"306","author":"BC N\u00e9meth","year":"2014","unstructured":"N\u00e9meth BC, Sahin-T\u00f3th M. Human cationic trypsinogen (PRSS1) variants and chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2014;306(6):G466\u201373.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"9","key":"14292_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/life14091055","volume":"14","author":"A Allemann","year":"2024","unstructured":"Allemann A, Staubli SM, Nebiker CA. Trypsin and trypsinogen activation peptide in the prediction of severity of acute pancreatitis. Life. 2024;14(9):1055.","journal-title":"Life"},{"issue":"1","key":"14292_CR31","doi-asserted-by":"publisher","first-page":"101497","DOI":"10.1016\/j.clinre.2020.07.004","volume":"45","author":"E Girodon","year":"2021","unstructured":"Girodon E, Rebours V, Chen JM, Pagin A, Levy P, Ferec C, et al. Clinical interpretation of PRSS1 variants in patients with pancreatitis. Clin Res Hepatol Gastroenterol. 2021;45(1):101497.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"21","key":"14292_CR32","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.3748\/wjg.v19.i21.3332","volume":"19","author":"F Gao","year":"2013","unstructured":"Gao F, Li YM, Hong GL, Xu ZF, Liu QC, He QL, et al. PRSS1_p.Leu81Met mutation results in autoimmune pancreatitis. World J Gastroenterol. 2013;19(21):3332\u20138.","journal-title":"World J Gastroenterol."},{"issue":"2","key":"14292_CR33","first-page":"449","volume":"5","author":"F Gao","year":"2012","unstructured":"Gao F, Liu QC, Zhang S, Zhuang ZH, Lin CZ, Lin XH. PRSS1 intron mutations in patients with pancreatic cancer and chronic pancreatitis. Mol Med Rep. 2012;5(2):449\u201351.","journal-title":"Mol Med Rep"},{"issue":"1","key":"14292_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s10020-019-0111-4","volume":"25","author":"Q Liu","year":"2019","unstructured":"Liu Q, Guo L, Zhang S, Wang J, Lin X, Gao F. PRSS1 mutation: a possible pathomechanism of pancreatic carcinogenesis and pancreatic cancer. Mol Med. 2019;25(1):44.","journal-title":"Mol Med"},{"issue":"1","key":"14292_CR35","first-page":"121","volume":"19","author":"H Wu","year":"2020","unstructured":"Wu H, Ding F, Chen X, Chen S, Shi Z, Liu Q, et al. PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma. Oncol Lett. 2020;19(1):121\u20136.","journal-title":"Oncol Lett"},{"issue":"5","key":"14292_CR36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.pan.2023.04.004","volume":"23","author":"E Masson","year":"2023","unstructured":"Masson E, Zou W-B, Pu N, Rebours V, G\u00e9nin E, Wu H, et al. Classification of PRSS1 variants responsible for chronic pancreatitis: an expert perspective from the Franco-Chinese GREPAN Study Group. Pancreatology. 2023;23(5):491\u2013506.","journal-title":"Pancreatology"},{"issue":"3","key":"14292_CR37","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3324\/haematol.2018.199356","volume":"104","author":"BO Wolthers","year":"2019","unstructured":"Wolthers BO, Frandsen TL, Patel CJ, Abaji R, Attarbaschi A, Barzilai S, et al. Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. Haematologica. 2019;104(3):556\u201363.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"14292_CR38","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1182\/blood-2023-185332","volume":"142","author":"H Levavi","year":"2023","unstructured":"Levavi H, Ahire D, Riazat-Kesh YJRA, Sheng T, Sastow DL, Feld J, et al. Array CGH + SNP in ALL enhances detection of complex cytogenetic profiles and suggests that PRSS1 loss may play a role in leukemogenesis. Blood. 2023;142(Supplement 1):6062.","journal-title":"Blood."},{"issue":"2","key":"14292_CR39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/cancers14020404","volume":"14","author":"Y Belotti","year":"2022","unstructured":"Belotti Y, Lim EH, Lim CT. The role of the extracellular matrix and tumor-infiltrating immune cells in the prognostication of high-grade serous ovarian cancer. Cancers. 2022;14(2):404.","journal-title":"Cancers."},{"key":"14292_CR40","doi-asserted-by":"publisher","first-page":"1200354","DOI":"10.3389\/fmolb.2023.1200354","volume":"10","author":"T Geng","year":"2023","unstructured":"Geng T, Zheng M, Wang Y, Reseland JE, Samara A. An artificial intelligence prediction model based on extracellular matrix proteins for the prognostic prediction and immunotherapeutic evaluation of ovarian serous adenocarcinoma. Front Mol Biosci. 2023;10:1200354.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"14292_CR41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/biolre\/ioy210","volume":"100","author":"VA Voronina","year":"2019","unstructured":"Voronina VA, Harris FM, Schmahl J, Galligan C, Oristian D, Zamfirova R, et al. Deletion of Adam6 in Mus musculus leads to male subfertility and deficits in sperm ascent into the oviduct. Biol Reprod. 2019;100(3):686\u201396.","journal-title":"Biol Reprod"},{"issue":"2","key":"14292_CR42","first-page":"39","volume":"3","author":"R Nunez","year":"2001","unstructured":"Nunez R. Flow cytometry: principles and instrumentation. Curr Issues Mol Biol. 2001;3(2):39\u201345.","journal-title":"Curr Issues Mol Biol"},{"issue":"9","key":"14292_CR43","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1073\/pnas.83.9.2934","volume":"83","author":"D Pinkel","year":"1986","unstructured":"Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A. 1986;83(9):2934\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"14292_CR44","first-page":"131","volume":"136","author":"J Anastasi","year":"1990","unstructured":"Anastasi J, Le Beau MM, Vardiman JW, Westbrook CA. Detection of numerical chromosomal abnormalities in neoplastic hematopoietic cells by in situ hybridization with a chromosome-specific probe. Am J Pathol. 1990;136(1):131\u20139.","journal-title":"Am J Pathol"},{"issue":"1","key":"14292_CR45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41598-024-84237-y","volume":"15","author":"S Oh","year":"2025","unstructured":"Oh S, Lee S-S, Jin H, Choi S-H, Cha C-K, Lee J, et al. A disintegrin and metallopeptidase domain (ADAM) 12, ADAM 17 mRNA and ADAM10 protein hold potential as biomarkers for detection of early gastric cancer. Sci Rep. 2025;15(1):763.","journal-title":"Sci Rep"},{"issue":"1","key":"14292_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41408-024-01133-4","volume":"14","author":"M Evers","year":"2024","unstructured":"Evers M, St\u00fchmer T, Schreder M, Steinbrunn T, Rudelius M, Jundt F, et al. Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma. Blood Cancer J. 2024;14(1):156.","journal-title":"Blood Cancer J"},{"issue":"6","key":"14292_CR47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/1541-7786.MCR-22-0384","volume":"21","author":"X Wang","year":"2023","unstructured":"Wang X, Zhu M, Zuo H, Hou G, Xie R. ADAM metallopeptidase domain 12 facilitates colorectal cancer progression by inhibiting hippo signaling pathway activity. Mol Cancer Res. 2023;21(6):525\u201334.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"14292_CR48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12094-022-02960-2","volume":"25","author":"H Wang","year":"2023","unstructured":"Wang H, Wu H, Chen Y. Serum ADAM metallopeptidase domain 12 as a promising diagnostic biomarker for breast and liver cancer. Clin Transl Oncol. 2023;25(2):473\u201381.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"14292_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/toxins8040122","volume":"8","author":"N Giebeler","year":"2016","unstructured":"Giebeler N, Zigrino P. A Disintegrin and Metalloprotease (ADAM): historical overview of their functions. Toxins (Basel). 2016;8(4):122.","journal-title":"Toxins (Basel)"},{"issue":"1","key":"14292_CR50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-016-0294-x","volume":"9","author":"H Mahmud","year":"2016","unstructured":"Mahmud H, Kornblau SM, ter Elst A, Scherpen FJG, Qiu YH, Coombes KR, et al. Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia. J Hematol Oncol. 2016;9(1):64.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"14292_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.yexcr.2017.05.019","volume":"357","author":"C Tian","year":"2017","unstructured":"Tian C, Yuan Z, Xu D, Ding P, Wang T, Zhang L, et al. Inhibition of glycolysis by a novel EGFR\/HER2 inhibitor KU004 suppresses the growth of HER2+ cancer. Exp Cell Res. 2017;357(2):211\u201321.","journal-title":"Exp Cell Res"},{"issue":"1","key":"14292_CR52","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12967-018-1732-z","volume":"16","author":"L Li","year":"2018","unstructured":"Li L, Peng M, Xue W, Fan Z, Wang T, Lian J, et al. Integrated analysis of dysregulated long non-coding RNAs\/microRNAs\/mRNAs in metastasis of lung adenocarcinoma. J Transl Med. 2018;16(1):372.","journal-title":"J Transl Med"},{"issue":"6","key":"14292_CR53","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1373\/clinchem.2013.213611","volume":"60","author":"CG Chiu","year":"2014","unstructured":"Chiu CG, Nakamura Y, Chong KK, Huang SK, Kawas NP, Triche T, et al. Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem. 2014;60(6):873\u201385.","journal-title":"Clin Chem"},{"issue":"6","key":"14292_CR54","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/pbc.25410","volume":"62","author":"NN Shah","year":"2015","unstructured":"Shah NN, Stevenson MS, Yuan CM, Richards K, Delbrook C, Kreitman RJ, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(6):964\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"14292_CR55","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","volume":"9","author":"EA Clark","year":"2018","unstructured":"Clark EA, Giltiay NV. CD22: a regulator of innate and adaptive B cell responses and autoimmunity. Front Immunol. 2018;9:2235.","journal-title":"Front Immunol"},{"issue":"26","key":"14292_CR56","doi-asserted-by":"publisher","first-page":"18769","DOI":"10.1074\/jbc.274.26.18769","volume":"274","author":"J Yohannan","year":"1999","unstructured":"Yohannan J, Wienands J, Coggeshall KM, Justement LB. Analysis of tyrosine phosphorylation-dependent interactions between stimulatory effector proteins and the B cell co-receptor CD22*. J Biol Chem. 1999;274(26):18769\u201376.","journal-title":"J Biol Chem"},{"issue":"4","key":"14292_CR57","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1074\/jbc.274.4.2303","volume":"274","author":"J Blasioli","year":"1999","unstructured":"Blasioli J, Paust S, Thomas ML. Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22*. J Biol Chem. 1999;274(4):2303\u20137.","journal-title":"J Biol Chem"},{"issue":"6","key":"14292_CR58","doi-asserted-by":"publisher","first-page":"a029215","DOI":"10.1101\/cshperspect.a029215","volume":"10","author":"C Chiasson-MacKenzie","year":"2018","unstructured":"Chiasson-MacKenzie C, McClatchey AI. Cell-cell contact and receptor tyrosine kinase signaling. Cold Spring Harb Perspect Biol. 2018;10(6):a029215.","journal-title":"Cold Spring Harb Perspect Biol."},{"issue":"35","key":"14292_CR59","doi-asserted-by":"publisher","first-page":"56129","DOI":"10.18632\/oncotarget.9794","volume":"7","author":"J Chen","year":"2016","unstructured":"Chen J, Wang H, Xu WP, Wei SS, Li HJ, Mei YQ, et al. Besides an ITIM\/SHP-1-dependent pathway, CD22 collaborates with Grb2 and plasma membrane calcium-ATPase in an ITIM\/SHP-1-independent pathway of attenuation of Ca2+i signal in B cells. Oncotarget. 2016;7(35):56129\u201346.","journal-title":"Oncotarget"},{"issue":"1","key":"14292_CR60","doi-asserted-by":"publisher","first-page":"1929725","DOI":"10.1080\/2162402X.2021.1929725","volume":"10","author":"A Raiter","year":"2021","unstructured":"Raiter A, Zlotnik O, Lipovetsky J, Mugami S, Dar S, Lubin I, et al. A novel role for an old target: CD45 for breast cancer immunotherapy. Oncoimmunology. 2021;10(1):1929725.","journal-title":"Oncoimmunology"},{"key":"14292_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.imlet.2018.01.009","volume":"196","author":"A Rheinl\u00e4nder","year":"2018","unstructured":"Rheinl\u00e4nder A, Schraven B, Bommhardt U. CD45 in human physiology and clinical medicine. Immunol Lett. 2018;196:22\u201332.","journal-title":"Immunol Lett"},{"issue":"1","key":"14292_CR62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-023-05520-y","volume":"103","author":"MAS Al Barashdi","year":"2024","unstructured":"Al Barashdi MAS, Ali A, McMullin MF, Mills K. CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy. Ann Hematol. 2024;103(1):73\u201388.","journal-title":"Ann Hematol"},{"key":"14292_CR63","doi-asserted-by":"publisher","first-page":"102562","DOI":"10.1016\/j.bcmd.2021.102562","volume":"89","author":"P Balasubramanian","year":"2021","unstructured":"Balasubramanian P, Singh J, Verma D, Kumar R, Bakhshi S, Tanwar P, et al. Prognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemia. Blood Cells Mol Dis. 2021;89:102562.","journal-title":"Blood Cells Mol Dis"},{"issue":"40","key":"14292_CR64","doi-asserted-by":"publisher","first-page":"64785","DOI":"10.18632\/oncotarget.11622","volume":"7","author":"L Saint-Paul","year":"2016","unstructured":"Saint-Paul L, Nguyen CH, Buffi\u00e8re A, Barros JPPd, Hammann A, Landras-Guetta C, et al. CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts. Oncotarget. 2016;7(40):64785.","journal-title":"Oncotarget."},{"issue":"12","key":"14292_CR65","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","volume":"19","author":"G Claps","year":"2022","unstructured":"Claps G, Faouzi S, Quidville V, Chehade F, Shen S, Vagner S, et al. The multiple roles of LDH in cancer. Nat Rev Clin Oncol. 2022;19(12):749\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"14292_CR66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fnins.2015.00022","volume":"9","author":"MJ Rogatzki","year":"2015","unstructured":"Rogatzki MJ, Ferguson BS, Goodwin ML, Gladden LB. Lactate is always the end product of glycolysis. Front Neurosci. 2015;9:22.","journal-title":"Front Neurosci"},{"issue":"3","key":"14292_CR67","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.apsb.2023.12.003","volume":"14","author":"M Liao","year":"2024","unstructured":"Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang J, et al. Targeting the Warburg effect: a revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer. Acta Pharmaceutica Sinica B. 2024;14(3):953\u20131008.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"12","key":"14292_CR68","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1080\/14712598.2021.1922666","volume":"21","author":"A Gonz\u00e1lez-Titos","year":"2021","unstructured":"Gonz\u00e1lez-Titos A, Hern\u00e1ndez-Camarero P, Barungi S, Marchal JA, Kenyon J, Per\u00e1n M. Trypsinogen and chymotrypsinogen: potent anti-tumor agents. Expert Opin Biol Ther. 2021;21(12):1609\u201321.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"14292_CR69","doi-asserted-by":"publisher","first-page":"957","DOI":"10.7150\/ijbs.52591","volume":"17","author":"D Ye","year":"2021","unstructured":"Ye D, Li Y, Zhang H, Zhou Z, Tang Y, Wu P, et al. Silencing PRSS1 suppresses the growth and proliferation of gastric carcinoma cells via the ERK pathway. Int J Biol Sci. 2021;17(4):957\u201371.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"14292_CR70","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.3390\/ijms22083814","volume":"22","author":"T-C Lin","year":"2021","unstructured":"Lin T-C. Functional Roles of SPINK1 in Cancers. Int J Mol Sci. 2021;22(8):3814.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"14292_CR71","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1038\/s41598-022-06946-6","volume":"12","author":"D Luo","year":"2022","unstructured":"Luo D, Liu D, Rao C, Shi S, Zeng X, Liu S, et al. Raised SPINK1 levels play a role in angiogenesis and the transendothelial migration of ALL cells. Sci Rep. 2022;12(1):2999.","journal-title":"Sci Rep"},{"key":"14292_CR72","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcimb.2020.00055","volume":"10","author":"A Niehrs","year":"2020","unstructured":"Niehrs A, Altfeld M. Regulation of NK-Cell Function by HLA Class II. Front Cell Infect Microbiol. 2020;10:55.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"14292_CR73","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12885-020-07222-4","volume":"20","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang H, Wang W, Liu W, Liu N, Liu S, et al. Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients. BMC Cancer. 2020;20(1):732.","journal-title":"BMC Cancer"},{"key":"14292_CR74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cca.2022.09.015","volume":"536","author":"L Zhang","year":"2022","unstructured":"Zhang L, Liu J, Qin X, Liu W. Platelet-acute leukemia interactions. Clin Chim Acta. 2022;536:29\u201338.","journal-title":"Clin Chim Acta"},{"issue":"D1","key":"14292_CR75","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"J-H Li","year":"2013","unstructured":"Li J-H, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein\u2013RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2013;42(D1):D92\u20137.","journal-title":"Nucleic Acids Res"},{"key":"14292_CR76","unstructured":"Chandar N, Viselli SM. Extracellular Matrix and Cell Adhesion. In: Lippincott\u00ae Illustrated Reviews: Cell and Molecular Biology. 3rd ed. 2023. pp. 11\u201331."},{"issue":"1","key":"14292_CR77","first-page":"9653244","volume":"2022","author":"S Bisht","year":"2022","unstructured":"Bisht S, Nigam M, Kunjwal SS, Sergey P, Mishra AP, Sharifi-Rad J. Cancer stem cells: from an insight into the basics to recent advances and therapeutic targeting. Stem Cells Int. 2022;2022(1):9653244.","journal-title":"Stem Cells Int"},{"issue":"1","key":"14292_CR78","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24(1):5.","journal-title":"Mol Cancer."},{"key":"14292_CR79","doi-asserted-by":"publisher","first-page":"217385","DOI":"10.1016\/j.canlet.2024.217385","volume":"611","author":"H Yu","year":"2025","unstructured":"Yu H, Li J, Peng S, Liu Q, Chen D, He Z, et al. Tumor microenvironment: nurturing cancer cells for immunoevasion and druggable vulnerabilities for cancer immunotherapy. Cancer Lett. 2025;611:217385.","journal-title":"Cancer Lett"},{"issue":"3","key":"14292_CR80","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cyto.990180302","volume":"18","author":"M Sartor","year":"1994","unstructured":"Sartor M, Bradstock K. Detection of intracellular lymphoid differentiation antigens by flow cytometry in acute lymphoblastic leukemia. Cytometry. 1994;18(3):119\u201322.","journal-title":"Cytometry"},{"issue":"11","key":"14292_CR81","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/intimm\/8.11.1743","volume":"8","author":"J Kirberg","year":"1996","unstructured":"Kirberg J, Broker T. CD45 up-regulation during lymphocyte maturation. Int Immunol. 1996;8(11):1743\u20139.","journal-title":"Int Immunol"},{"key":"14292_CR82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.imlet.2018.01.009","volume":"196","author":"A Rheinl\u00e4nder","year":"2018","unstructured":"Rheinl\u00e4nder A, Schraven B, Bommhardt U. CD45 in human physiology and clinical medicine. Immunol Lett. 2018;196:22\u201332.","journal-title":"Immunol Lett"},{"issue":"9","key":"14292_CR83","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.3390\/ijms25094609","volume":"25","author":"SA Kust","year":"2024","unstructured":"Kust SA, Ustiuzhanina MO, Streltsova MA, Shelyakin PV, Kryukov MA, Lutsenko GV, et al. HLA-DR expression in natural killer cells marks distinct functional states, depending on cell differentiation stage. Int J Mol Sci. 2024;25(9):4609.","journal-title":"Int J Mol Sci."},{"key":"14292_CR84","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.canlet.2019.10.003","volume":"467","author":"N Saha","year":"2019","unstructured":"Saha N, Robev D, Himanen JP, Nikolov DB. ADAM proteases: emerging role and targeting of the non-catalytic domains. Cancer Lett. 2019;467:50\u20137.","journal-title":"Cancer Lett"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14292-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14292-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14292-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T07:02:25Z","timestamp":1747465345000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14292-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14292"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14292-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethical committee, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt (Msc: no. 85), and all participants were accorded informed consent before their enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"884"}}